Akynzeo

Active Ingredient(s): Netupitant + Palonosetron Hydrochloride
FDA Approved: * October 10, 2014
Pharm Company: * HELSINN HLTHCARE
Category: Nausea & Vomiting

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Akynzeo Overview

Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV—nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.[1] Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy,[2] or as a single oral capsule one hour before chemotherapy.&am...

Read more Akynzeo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Palonosetron

Recent Akynzeo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Netupitant + Palonosetron Hydrochloride
  • Capsule: 300mg + 0.5mg
  • Injection: 235mg + 0.25mg
  • Powder: 235mg + 0.25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Akynzeo: (3 results)

Sorted by National Drug Code
  • 62856-796 Akynzeo Oral Capsule by Eisai Inc.
  • 69639-101 Akynzeo Oral Capsule by Helsinn Therapeutics (U.s.), Inc.
  • 69639-102 Akynzeo Intravenous Injection by Helsinn Therapeutics (U.s.), Inc.

Drugs with one or more similar ingredients: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA